Latest Immunotherapy Treatments
Studies show that durvalumab and tremelimumab work very well together while treating mesothelioma. A phase I clinical trial was performed at the Baylor College of Medicine in conjunction with Baylor St. Luke’s Medical Center. Durvalumab is an immunotherapy drug known as a PD-1/PD-L1 checkpoint inhibitor. It works by blocking the connection between T-cell receptors and…
An immune system boosting therapy could potentially be used to treat mesothelioma. For a long period of time, chemotherapy drugs have been the standard drug to fight mesothelioma, but researchers believe bevacizumab could change this and be used alongside standard mesothelioma treatments. Chemotherapy is popular with doctors, but chemotherapy drugs are cytotoxic, which means they…
Researchers are looking into changing mesothelioma cells to make them more susceptible to immunotherapy. Mesothelioma is a hard cancer to treat, so new approaches need to be developed to try to lengthen and improve mesothelioma patients’ lives. Immunotherapy can work well for some, but for others it does very little, so researchers need to find…
A new treatment utilizing CAR-T cell therapy could help prevent mesothelioma cells from protecting themselves. The treatment, called UCARTMESO, is being developed by the French biopharmaceutical company Cellectis. The treatment works by targeting cells that overexpress mesothelin, which is an antigen that prevents cells from sending immune suppressive signals. A majority of the time immune…
Combining the drug ramucirumab with the chemotherapy drug gemcitabine is showing to be a successful second line treatment for pleural mesothelioma. Ramucirumab is a type of immunotherapy drug called a monoclonal antibody, which targets and restricts proteins that stimulate blood vessel growth in tumors. The Lancet Oncology published the results of the Italian study involving…
Researchers at the Memorial Sloan Kettering Cancer Center are experimenting with a combination of CAR-T cell therapy and Keytruda, a PD-1 blocker for the treatment of pleural mesothelioma. This is the first time that these two therapies have been combined. The results were recently published in Cancer Discovery. Mesothelioma is an aggressive cancer of the…
Research could help create better and safer immunotherapy treatments for mesothelioma. Immunotherapy is a fast growing and exciting way to treat cancer because it uses the body’s own immune system to treat cancer instead of harmful drugs like chemotherapy. Immunotherapy can be way more effective than typical treatments, but it can also have very bad…
A new cancer vaccine was found to be effective in mesothelioma patients alongside Opdivo in a new study. It was studied in people whose cancer no longer responded to standard chemotherapy. The phase I clinical trial took place at the Memorial Sloan Kettering Cancer Center and it involved the galinpepimut-S vaccine, or GPS. Data early…
An Italian study has found that the combination of two immunotherapy drugs can create a long-term survival in mesothelioma patients. The two drugs, tremelimumab and durvalumab, were just given orphan drug status to treat liver cancer in the last year. The best results in the mesothelioma study were seen in patients with a high level…
There is promising new data from the makers of ONCOS-102 that shows that the treatment can help improve the long-term survival of mesothelioma patients. ONCOS-102 was recently given Fast-Track approval by the FDA to speed up its development. ONCOS-102 is a modified adenovirus that infects cancer cells. The new mesothelioma patient data is showing that…
